Reuters logo
Transcept's drug for obsessive compulsive disorder fails trial
December 21, 2012 / 12:45 PM / 5 years ago

Transcept's drug for obsessive compulsive disorder fails trial

(Reuters) - Transcept Pharmaceuticals Inc said a mid-stage trial of its experimental drug for obsessive compulsive disorder did not meet the main goal of showing improvements in treating symptoms better than a placebo.

The company expects to complete the remaining analyses in early 2013 and will decide on the future development of the drug, TO-2061, after further review of the data.

The trial was testing the drug in patients with obsessive compulsive disorder who had not adequately responded to treatment with approved first-line therapies.

Reporting by Esha Dey in Bangalore; Editing by Don Sebastian

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below